May 10 (Reuters) - COVID-19 vaccine maker Novavax ( NVAX )

, on Friday, erased doubts about its ability to remain

in business by removing a so-called "going concern" notice.

In February last year, Novavax ( NVAX ) had raised doubts about its

ability to remain in business and announced plans to slash

spending as it worked to prepare for a fall vaccination

campaign.

The company also said on Friday that its revenue rose to $94

million in the first quarter, from $81 million in the same

period in 2023.